Literature DB >> 6693195

Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans.

J S Gronowitz, F R Källander, H Diderholm, H Hagberg, U Pettersson.   

Abstract

An improved method for the detection of deoxythymidine kinase (TK) in human sera is reported. The method which utilizes 125I-iododeoxyuridine (IdUrd) as a substrate was used to measure TK in sera from patients with different diseases. Sera collected during the acute stage of infectious mononucleosis were found to contain elevated levels of TK, in most cases 10-40 times the normal value. The serum TK activity disappeared gradually and reached a normal level within 4 weeks. Sera from patients with other viral infections contained in most cases normal serum TK levels except in connection with measles, rubella, varicella, herpes simplex virus and cytomegalovirus infections. Additional studies revealed that sera from patients with different types of advanced lymphomas, acute leukemias, chronic granulocytic leukemia and lung cancer of the small-cell type with metastases, contained high TK levels which fluctuated in parallel with alterations in activity of the disease. The TK activity in sera from patients with both mononucleosis and tumor disease was characterized by electrophoresis and by its ability to utilize cytidine triphosphate as the phosphate donor. The results showed that the serum TK has the same properties as the human cytosolar TKI, except in connection with varicella.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693195     DOI: 10.1002/ijc.2910330103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Structures of thymidine kinase 1 of human and mycoplasmic origin.

Authors:  Martin Welin; Urszula Kosinska; Nils-Egil Mikkelsen; Cecilia Carnrot; Chunying Zhu; Liya Wang; Staffan Eriksson; Birgitte Munch-Petersen; Hans Eklund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

Review 2.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

3.  Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung.

Authors:  V Abbasciano; L Graziano; D Arcudi; G Felisatti; A R Cavallini; M G Reali; N Calia; S Campi; C Guglielmini
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

4.  XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.

Authors:  Georgios Gakis; Joerg Hennenlotter; Marcus Scharpf; Joachim Hevler; David Schilling; Ursula Kuehs; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2010-11-27       Impact factor: 4.226

5.  Thymidine kinase in extracts of human brain tumours.

Authors:  L Persson; S J Gronowitz; C F Källander
Journal:  Acta Neurochir (Wien)       Date:  1986       Impact factor: 2.216

6.  Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA.

Authors:  A R Karlström; M Neumüller; J S Gronowitz; C F Källander
Journal:  Mol Cell Biochem       Date:  1990-01-18       Impact factor: 3.396

7.  Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.

Authors:  M Hallek; B Emmerich; S Strohmeyer; R Busch; A Reichle; R Senekowitsch
Journal:  Klin Wochenschr       Date:  1988-08-15

8.  Deoxythymidine-kinase in cerebrospinal fluid: a new potential "marker" for brain tumours.

Authors:  J S Gronowitz; C F Källander; H Hagberg; L Persson
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

9.  Elevated serum thymidine kinase activity in patients with acute viral hepatitis.

Authors:  K Tanaka; T Sishido; M Morimoto; S Inoue; Y Takamura; M Masumura
Journal:  Gastroenterol Jpn       Date:  1993-02

10.  Inhibition of herpes simplex virus production in vitro by cyclosporin A.

Authors:  A Vahlne; P A Larsson; P Horal; J Ahlmén; B Svennerholm; J S Gronowitz; S Olofsson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.